One patient developed a contrast allergy after application of gadolinium.
In this context, by developing a contrast agent targeted to this specific biomarker, it will be possible to provide us with insights into molecular understanding of atherosclerosis and to potentially offer a tool of clinical diagnosis.
To develop a technique for contrast infusion sonography and assess the possible use in determining microinsert placement and tubal status after Essure® sterilization.
In vitro and in vivo experiments were performed with 20-nm particles; USPIO was used because the purpose of this study was to develop a novel MRI contrast agent for the detection of lymph nodes.
The aim of this present study is to develop a molecular imaging contrast agent for selective identification of hydroxyapatite calcification in human osteotropic tumor tissues ex vivo and in human osteosarcoma cells in vitro.
Ideally, only a few copies of the aptamers per gold nanoparticles are necessary to develop a molecular-specific contrast agent for reflectance imaging.
The overall goal of this work was to develop a methodology for directly contrasting the production and environmental concerns of N management in agricultural systems.
We developed a novel contrast agent of "foam state" to maintain contrast effect for enough time and performed a comparative study of physical properties and its usefulness in experimental intervention in animal model.
Osteosarcoma cells U2OS accumulated higher levels of p21, similar to U343MGa cells cells, but did in contrast develop a more pronounced senescence-like morphology.
We elaborated the Ding-Sperling model, originally developed and successfully applied to model binocular phase combination, to develop a new multi-pathway contrast-gain control model (MCM, Figures 4 and Text S1).
